OncoSec Medical 미래 성장

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 OncoSec Medical 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

OTCPK:ONCS.Q - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
1/31/2023	N/A	-29	-25	-25	N/A
10/31/2022	N/A	-32	-29	-28	N/A
7/31/2022	N/A	-34	-32	-32	N/A
4/30/2022	N/A	-38	-34	-34	N/A
1/31/2022	N/A	-41	-42	-41	N/A
10/31/2021	N/A	-42	-43	-42	N/A
7/31/2021	N/A	-45	-43	-42	N/A
4/30/2021	N/A	-42	-44	-43	N/A
1/31/2021	N/A	-43	-38	-38	N/A
10/31/2020	N/A	-46	-35	-35	N/A
7/31/2020	N/A	-42	-33	-33	N/A
4/30/2020	N/A	-41	-32	-32	N/A
1/31/2020	N/A	-38	-31	-31	N/A
10/31/2019	N/A	-32	-30	-30	N/A
7/31/2019	N/A	-30	-29	-29	N/A
4/30/2019	N/A	-35	-27	-27	N/A
1/31/2019	N/A	-38	-25	-25	N/A
10/31/2018	N/A	-41	-25	-25	N/A
7/31/2018	N/A	-39	-23	-23	N/A
4/30/2018	N/A	-33	-22	-22	N/A
1/31/2018	N/A	-27	-20	-20	N/A
10/31/2017	N/A	-22	-18	-18	N/A
7/31/2017	N/A	-21	-17	-17	N/A
4/30/2017	N/A	-22	-17	-17	N/A
1/31/2017	N/A	-24	-18	-17	N/A
10/31/2016	N/A	-25	N/A	-18	N/A
7/31/2016	N/A	-27	N/A	-18	N/A
4/30/2016	N/A	-27	N/A	-19	N/A
1/31/2016	N/A	-27	N/A	-19	N/A
10/31/2015	N/A	-24	N/A	-19	N/A
7/31/2015	N/A	-21	N/A	-18	N/A
4/30/2015	N/A	-18	N/A	-15	N/A
1/31/2015	N/A	-16	N/A	-13	N/A
10/31/2014	N/A	-14	N/A	-10	N/A
7/31/2014	N/A	-12	N/A	-9	N/A
4/30/2014	N/A	-10	N/A	-8	N/A
1/31/2014	N/A	-8	N/A	-7	N/A
10/31/2013	N/A	-7	N/A	-6	N/A
7/31/2013	N/A	-7	N/A	-6	N/A
4/30/2013	N/A	-7	N/A	-6	N/A
1/31/2013	N/A	-6	N/A	-5	N/A
10/31/2012	N/A	-7	N/A	-5	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ONCS.Q 의 예상 수익 증가율이 절약률( 2.1% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: ONCS.Q 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: ONCS.Q 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: ONCS.Q 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: ONCS.Q 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ONCS.Q 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

OncoSec Medical 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target decreased to US$5.00

Price target decreased to US$5.00

Forecast to breakeven in 2024

Price target raised to US$8.13

Recent updates

OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million.

Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program

High number of new directors

OncoSec Medical Incorporated Receives Notice from the Nasdaq Stock Market LLC

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated Presents Encouraging Early Data with TAVO™-EP combined with Nivolumab (Opdivo®) in Neoadjuvant Melanoma

Oncosec Medical Incorporated Announces Positive Clinical Data of the Keynote-695 Trial Assessing Tavo-Ep in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to Anti-Pd-1 Treatment

OncoSec Medical Incorporated Elects Robert H. Arch as Non-Independent Director of the Board

OncoSec Medical Incorporated Elects Stephany Foster as an Independent Director

OncoSec Medical Incorporated Announces Workforce Reduction

OncoSec to cut workforce by 45% as part of corporate restructuring

OncoSec Medical Incorporated Appoints Joon Kim to the Audit Committee

OncoSec Medical Incorporated, Annual General Meeting, Nov 23, 2022

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated Appoints Robert H. Arch as Chief Executive Officer

Price target decreased to US$5.00

Less than half of directors are independent

OncoSec Medical Incorporated, Annual General Meeting, Jul 12, 2022

Price target decreased to US$5.00

OncoSec Medical Incorporated Announces Appointment of George Chi as Chief Financial Officer

Oncosec Medical Receives Notice from the Nasdaq Stock Market

Less than half of directors are independent

Interim CEO & COO Brian Leuthner has left the company

Forecast to breakeven in 2024

President, CEO & Director Daniel O'Connor has left the company

OncoSec Medical Incorporated, Annual General Meeting, Apr 29, 2021

Price target raised to US$8.13

OncoSec Medical Incorporated Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, Tavo™, in Triple Negative Breast Cancer

OncoSec Medical Incorporated Appoints Bridget O'keeffe as Vice President of Clinical Development

OncoSec Medical Incorporated Announces Management Appointments

New 90-day high: US$7.71

OncoSec Announces First Subjects Dosed in Phase 1 Trial of Corvax12, Oncosec's Covid-19 Vaccine Candidate Combining Interleukin-12 (Il-12) with an Enhanced Sars-Cov-2 Spike Protein

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $42.026498 million.

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

New 90-day high: US$6.81

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

Dosing underway in OncoSec's Tavo combo trial in skin cancer

New 90-day high: US$6.65

OncoSec Medical Incorporated Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO and its Gene Electrotransfer Technology

OncoSec Medical Incorporated Announces Exclusive License Agreement for Cliniporator Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics

OncoSec: Undervalued And Continuing To Make Progress

OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

New 90-day high: US$5.11

OncoSec Medical Incorporated to Present Positive Interim Data from Keynote-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19

OncoSec Medical Incorporated Announces Stepping Down of Kellie Malloy Foerter as Chief Operating Officer

OncoSec Medical Incorporated Announces Appointment of Sandra Aung as Senior Vice President, Chief Clinical Development Officer

OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO and Its Gene Delivery Platform

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $14.977914 million.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견